首页> Journal of thrombosis and thrombolysis> Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial.

Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial.

导出原文传递

翻译打印收藏纠错

第一作者： Sebastian,Werth

第一单位： Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital "Carl Gustav Carus", Technical University Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.

作者： Sebastian,Werth ^[1] ; Rupert,Bauersachs ^[2] ; Horst,Gerlach ^[3] ; Eberhard,Rabe ^[4] ; Sebastian,Schellong ^[5] ; Jan,Beyer-Westendorf ^[6]

作者单位： Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital "Carl Gustav Carus", Technical University Dresden, Fetscherstrasse 74, 01307, Dresden, Germany. ^[1] Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany.;Center of Thrombosis and Hemostasis, University of Mainz, Mainz, Germany. ^[2] Private Office for Vascular Diseases, Mannheim, Germany. ^[3] Department of Dermatology, University of Bonn, Bonn, Germany. ^[4] Medical Department II, Dresden Friedrichstadt Hospital, Dresden, Germany. ^[5] Center for Vascular Medicine and Department of Medicine III, Division of Angiology, University Hospital "Carl Gustav Carus", Technical University Dresden, Fetscherstrasse 74, 01307, Dresden, Germany. jan.beyer@uniklinikum-dresden.de.;Thrombosis Service, Kings College, London, UK. jan.beyer@uniklinikum-dresden.de. ^[6]

关键词 Fondaparinux Rivaroxaban Superficial vein thrombosis Thrombophlebitis